Troxagliptin Succinate API

Name	Troxagliptin succinate
Chinese name	琥珀酸曲格列汀
Cas Number	1029877-94-8
Source	India
Qualifications	-/-/-/-/-

The original research was the Japanese pharmaceutical giant Takeda, and it was approved for listing in Japan in 2015. Troxagliptin is an ultra-long-acting dipeptidyl peptidase IV (DPP-4) inhibitor, suitable for the treatment of type 2 diabetes. This product is the first hypoglycemic drug to be taken orally once a week in the world, and similar DPP-4 inhibitors on the market need to be taken orally once a day. As an ultra-long-acting DPP-4 inhibitor, troxagliptin succinate controls blood glucose levels by selectively and continuously inhibiting DPP-4. Compared with the current short-acting products on the market once a day, it is expected to greatly improve patients Convenience and compliance, and can potentially improve blood sugar control and reduce diabetes complications; on the other hand, troxagliptin succinate only inhibits the inactivation of incretin when blood sugar is high, and when blood sugar reaches normal When the level is low or low, it does not exert an inhibitory effect. Therefore, compared with traditional insulin and hypoglycemic drugs that still lower blood sugar during hypoglycemia, troxagliptin can better avoid the occurrence of hypoglycemia. Since its launch, it has received great attention from the medical community, providing more convenient treatment for diabetic patients, and its clinical value and clinical status may be expected to improve.

Hot Tags: troxagliptin succinate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Bemeprost API, Celecoxib API, Paliperidone API, Adapalene API, Bosentan API, Tavaborol API

• Previous: Teriflunomide API
• Next: Lurasidone Hydrochloride API